Grifols Class A/€GRF
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Grifols Class A
Grifols SA, operating under the ticker GRF, is a biopharmaceutical company specialized in the production of plasma-derived medicines. Founded in 1940 and headquartered in Barcelona, Spain, Grifols is engaged in the diagnosis, prevention, and treatment of a variety of diseases, with a strong focus on immunology, hematology, and intensive care sectors. The company operates globally, leveraging advanced technologies and rigorous quality processes to provide essential medical products.
- Ticker
- €GRF
- Sector
- Health
- Primary listing
- BME
- Employees
- 25,258
- Headquarters
- Barcelona, Spain
- Website
- www.grifols.com
Grifols Class A Metrics
BasicAdvanced
€6.5B
16.39
€0.66
1.19
€0.07
0.62%
Price and volume
Market cap
€6.5B
Beta
1.19
52-week high
€12.14
52-week low
€8.46
Average daily volume
1.5M
Dividend rate
€0.07
Financial strength
Current ratio
2.373
Quick ratio
0.686
Long term debt to equity
1.104
Total debt to equity
1.172
Dividend payout ratio (TTM)
28.32%
Interest coverage (TTM)
2.24%
Profitability
EBITDA (TTM)
1,559.231
Gross margin (TTM)
37.40%
Net profit margin (TTM)
6.09%
Operating margin (TTM)
17.60%
Effective tax rate (TTM)
19.16%
Revenue per employee (TTM)
€290,000
Management effectiveness
Return on assets (TTM)
4.23%
Return on equity (TTM)
6.93%
Valuation
Price to earnings (TTM)
16.392
Price to revenue (TTM)
0.997
Price to book
1.18
Price to tangible book (TTM)
-1.53
Price to free cash flow (TTM)
11.526
Free cash flow yield (TTM)
8.68%
Free cash flow per share (TTM)
0.939
Dividend yield (TTM)
0.62%
Growth
Revenue change (TTM)
-0.33%
Earnings per share change (TTM)
46.08%
3-year revenue growth (CAGR)
4.63%
10-year revenue growth (CAGR)
6.41%
3-year earnings per share growth (CAGR)
329.35%
10-year earnings per share growth (CAGR)
-1.77%
What the Analysts think about Grifols Class A
Analyst ratings (Buy, Hold, Sell) for Grifols Class A stock.
Analyst projections of the future price of Grifols Class A stock.
Bulls say / Bears say
Immunoglobulins are a clear growth engine: in the first half of 2026, Biopharma revenue rose 5.4% at constant currency and immunoglobulin revenue grew 12.8%. (Grifols)
Grifols’ Egyptian plasma platform could improve supply resilience and sourcing economics. The company is expanding the project and aims to reach annual collection capacity of up to three million litres by 2029. (Grifols)
Near-term refinancing risk has eased: Grifols refinanced all its 2027 maturities, has about €2 billion of liquidity and no significant debt maturities until the fourth quarter of 2028. (U.S. Securities and Exchange Commission)
Leverage remains high at 4.2 times net debt to EBITDA, while first-half free cash flow before M&A was only €91 million. Sustained cash generation is needed to make meaningful progress on debt reduction. (U.S. Securities and Exchange Commission)
Growth is uneven: first-half albumin revenue fell 14.2% at constant currency, mainly reflecting lower prices in China, leaving total revenue growth at just 2.6%. (U.S. Securities and Exchange Commission)
Governance concerns remain an overhang: recent reporting says Spain’s market regulator required Grifols to restate accounts, while the company’s US defamation case against Gotham remains contested ahead of a planned 2027 trial. (The Objective, Cinco Días)
Data summarised monthly by Lightyear AI. Last updated on 18 Oct 2026.
Grifols Class A Financial Performance
Revenues and expenses
Grifols Class A Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Grifols Class A
AllEURUSDGBP
Fund name | Fund size | €GRF weighting |
|---|---|---|
Xtrackers Spain€XESD | €282M | 0.37% |
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.19% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.19% |
iShares STOXX Europe 600 Health Care€EXV4 | €709M | 0.17% |
iShares Dow Jones Eurozone Sustainability Screened€EXXV | €217M | 0.13% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.